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Abstract
Prostate‐specific antigen (PSA) plays an important role in the diagnosis and manage‐
ment of prostate cancer. The utility of PSA has been extended to a number of parame‐
ters which may guide clinical decision‐making in subsequent treatment. This book
chapter systematically reviewed the current evidence of PSA and PSA kinetics in the
management  of  advanced  prostate  cancer.  Results  showed  that  the  prognostic
significance  of  pre‐treatment  PSA  level  is  uncertain.  PSA  nadir  predicts  survival
outcomes but may be confounded by the pre‐treatment PSA level, and the PSA nadir
may only be known after there is a PSA rise in subsequent follow‐up. Time to PSA nadir
has some prognostic significance but is limited by the potential immortal bias. Evidence
on the use of PSA doubling time is limited and the different calculation methodolo‐
gies render difficulties in generalization of such parameter. PSA progression is the best
surrogate marker of survival and can be considered as the primary endpoint in future
clinical trials. PSA response predicts survival but has not been shown prospectively to
be a surrogate of clinical benefit. PSA and its kinetics should play an important role in
the  management  of  advanced  prostate  cancer  and  should  be  utilized  in  a  more
standardized manner.
Keywords: prostate cancer, prostate‐specific antigen, prostate‐specific antigen nadir,
time to prostate‐specific antigen nadir, prostatic‐specific antigen doubling time, pros‐
tate‐specific antigen progression, prostate‐specific antigen response
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1. Introduction
The first study investigating tissue‐specific antibodies in the human prostate can be traced back
to 1969 by Ablin et al. [1]. Nadji et al. [2] later characterized prostate‐specific antigen (PSA) as a
potential immunohistologic marker for prostatic neoplasms. The landmark article by Stamey
et al. [3] showed that serum PSA has a much better performance than prostatic acid phospha‐
tase in the detection of prostate cancer, and appeared to be useful in detecting residual or early
recurrence of tumour, and in monitoring response to primary treatment. It has led to exten‐
sive researches in this area, and the discovery of PSA has revolutionized the management of
prostate cancer, from early detection to definitive treatment and monitoring of the disease. The
utility of PSA has been extended to a number of parameters that may have prognostic signifi‐
cance in prostate cancer and hence has gained wide interest in the past two decades.
2. Objectives
In this chapter, we systemically reviewed and appraised the current role of PSA and PSA
kinetics in the management of advanced prostate cancer. We further discussed the potential
benefits and controversies of the different PSA‐related parameters.
3. Methods
A systematic search was conducted in the PubMed database through November 2015 using
the following terms: ‘prostate cancer’, ‘prostate‐specific antigen’, ‘prostate‐specific antigen
nadir’, ‘time to prostate‐specific antigen nadir’, ‘prostatic‐specific antigen doubling time’,
‘prostate‐specific antigen progression’ and ‘prostate‐specific antigen response’. Only original
full research articles published in English with full‐length text available were reviewed. A
manual search using the Web‐based search engine Google Scholar was also performed.
Reference lists of the retrieved articles were reviewed for other relevant studies.
4. Results
4.1. Pre‐treatment PSA level
To a certain extent, the pre‐treatment PSA level may reflect the volume of cancer cells, and
hence, it is a parameter of interest in predicting disease prognosis. However, it does not reflect
the sensitivity of cancer cells in response to subsequent therapy, in particular hormonal therapy
in the context of metastatic disease. The prognostic significance of pre‐treatment PSA level is
uncertain. Some studies showed that higher pre‐treatment PSA level was associated with
disease progression, cancer‐specific mortality and all‐cause mortality [4–14], while other
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studies either showed no association or failed to demonstrate statistical significance upon
multivariate analyses [15–32]. The wide range of pre‐treatment PSA level in metastatic disease
also limited its clinical application.
4.2. PSA nadir
PSA nadir was defined as the lowest PSA level achieved after the initiation of treatment. An
undetectable PSA nadir level reflects that most if not all of the prostate cancer cells are
androgen‐sensitive, while any detectable PSA level reflects the presence of androgen‐insensi‐
tive prostate cancer cells. This was supported by a study which showed that patients who had
biochemical relapse following 3 months of neoadjuvant androgen deprivation therapy and
radical prostatectomy had greater PSA mRNA levels and more intense PSA immunostaining
despite castrate levels of testosterone, than patients who did not relapse, yet they had similar
levels of androgen receptor gene expression and protein staining [33]. The majority of the
literature showed that PSA nadir is consistent in predicting disease prognosis. A higher PSA
nadir level has been shown to be associated with biochemical or disease progression [4, 15, 19,
25, 31, 32, 34–37], prostate cancer‐specific mortality [6, 7, 16, 22, 25, 38–40] and all‐cause
mortality [6, 15, 16, 24, 26, 29, 30, 41–44]. However, there is no absolute threshold level for PSA
nadir being recognized by any regulatory agency, and cut‐off values at 0.2 ng/mL, 1.0 ng/mL
and 4.0 ng/mL have been proposed in various studies. In particular, the drop of PSA to < 4.0 
ng/mL has commonly been recognized as PSA normalization, and similar to PSA nadir, PSA
normalization was associated with better progression‐free survival, cancer‐specific survival
and overall survival [35, 39, 43, 44]. However, PSA nadir may be affected by the pre‐treatment
PSA level, rendering difficulty in clinical application, and the PSA nadir may only be known
after there is a PSA rise in subsequent follow‐up.
4.3. Time to PSA nadir
Time to PSA nadir was defined as the duration needed for the PSA level to reach its nadir after
the initiation of treatment. Upon hormonal therapy, one may expect the PSA level to drop to
its nadir within a shorter period of time in case of hormone‐sensitive prostate cancer, but the
ability to have sustained continuous suppression over a longer period of time may be as
important. The majority of the studies showed that a longer time to PSA nadir was associated
with better outcomes including biochemical or disease progression, cancer‐specific survival
and overall survival [15, 16, 26, 29, 34, 36]. The other studies either showed the contrary or did
not detect any associations between them [6, 22, 23, 31]. Due to the potential immortal time
bias, the relationship between time to PSA nadir and survival has to be interpreted with caution
[45]. For example, one must have survived 12 months in order to have a time to PSA nadir of
12 months. Hence, this immortal time bias favours a positive correlation between time to PSA
nadir and survival outcomes. In order to minimize this potential bias, one study attempted to
investigate the prognostic significance of time to PSA nadir using survival beyond time to PSA
nadir as an alternative outcome measurement. It has been shown that a longer time to PSA
nadir was associated with better survival beyond time to PSA nadir [45]. A longer time to PSA
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nadir was also shown to be associated with a lower PSA velocity after progression, but whether
PSA velocity after progression can be a surrogate for survival is doubtful [46].
4.4. PSA doubling time
PSA doubling time can generally be interpreted as the time needed for the PSA level to double
itself. It assumes an exponential increase in serum PSA and first‐order kinetics and can be
calculated by natural logarithm of 2 divided by the slope of the relationship between the
logarithm of PSA and time of PSA measurement [47]. However, several other calculation
models have been proposed, and there is no standardization in the calculation of PSA doubling
time. A shorter PSA doubling time has been shown to predict metastasis after prior radical
prostatectomy [27, 28, 47], disease progression [32, 48], prostate cancer‐specific mortality [6, 7,
22, 23, 25, 40, 49–51] and all‐cause mortality [6, 9, 24, 27, 38, 52–54]. The utility of PSA doubling
time has been widespread, yet the inconsistencies in the methodologies in calculating PSA
doubling time [55] and the complicated logarithm calculations involved limited its use in
clinical practice. Small deviations from the different methods of calculations may also lead to
wide variations in the calculated PSA doubling time [55]. In 2008, the Prostate Cancer Clinical
Trials Working Group (PCWG2) discourages the use of PSA doubling time as the primary
endpoint in clinical trials because its significance is uncertain [56]. A subsequent systematic
review also concluded that the evidence on PSA doubling time is limited and there is no
justification for the use of PSA doubling time to guide decision‐making in subsequent
treatment [57].
4.5. PSA progression
PSA progression is commonly used as an endpoint in clinical trials, and it was generally
thought to represent disease progression and hence reflect the survival outcomes. However,
in particular for metastatic disease, multiple definitions of PSA progression have been
proposed; they rendered difficulties comparing the results between different studies and
limited the generalization of the utility of PSA progression. In 1999, Prostate‐specific Antigen
Working Group (PCWG1) made consensus recommendations for different outcome measures
in clinical trials in prostate cancer [58]. PCWG1 defined PSA progression as a >50% increase
from nadir and an increase of at least 5 ng/mL, or back to baseline, whichever was lowest. In
2008, PCWG2 proposed another definition for PSA progression, recognizing that early changes
in PSA should not be used for clinical decision‐making [56]. For those with PSA decline from
baseline, PSA progression was defined as an increase in PSA by ≥25% and ≥2 ng/mL above the
nadir, which should be confirmed by a second value 3 or more weeks later; for those with no
PSA decline, PSA progression was defined as an increase in PSA ≥25% and ≥2 ng/mL after
12 weeks. Hussain et al. [44] reviewed the data from two large‐scale clinical trials, namely the
Southwest Oncology Group (SWOG) 9346 trial on intermittent ADT and the SWOG 9916 trial
on docetaxel. It was shown that both PCWG1 and PCWG2 definitions of PSA progression
predicted a 2.4‐fold increase in risk of death and a more than 4‐fold increase in the risk of death
if PSA progression occurred in the first 7 months. This important study demonstrated that PSA
progression is a significant predictor of survival in patients who have newly diagnosed
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metastatic hormone‐sensitive prostate cancer as well as in those with castration resistant
prostate cancer treated with chemotherapy. The authors suggested that the PCWG2 definition
might be more appealing as patients are identified with progression relatively earlier on.
Pooling data from 9 cancer and leukaemia Group B trials [11], both PCWG1 and PCWG2
definitions of PSA progression were shown to be significant predictors of overall survival with
hazard ratios of 1.44 (95% CI 1.28–1.62, P < 0.001) and 1.43 (95% CI 1.27–1.61, P < 0.001),
respectively. The above evidence formed the basis of using PSA progression as the primary
endpoint in various clinical trials.
4.6. PSA response
PSA response was determined by the degree of decline from its pre‐treatment level. The
PCWG1 [58] defined PSA response as a decline of >50% from baseline, measured twice 3–4
weeks apart. Several studies have shown that a PSA decline of >50% was associated with better
cancer‐specific survival [39, 59] and overall survival [17, 18, 60–62]. However, post hoc analyses
in both SWOG 9916 [63] and TAX 327 [43] trials on the use of docetaxel showed that a PSA
decline of >30% might be a better surrogate marker for survival than a PSA decline of >50%
based on the proportion of treatment effect and the proportion of variation. A subsequent
combined analysis on the SWOG 9346 and SWOG 9916 trials [44] showed that a PSA decline
of >30% was associated with better overall survival. However, PCWG2 [56] advised against
reporting PSA response rates in clinical trials. Concerns were raised about the strength of
association between PSA decline and survival, and no criterion, be it >50% or >30% decline in
PSA, has been shown prospectively to be a surrogate of clinical benefit [64]. Instead, PCWG2
recommended the use of waterfall plot to provide a broader and more sensitive display of data.
On the other hand, following the discovery of AR‐V7 splice variant [65], it was proposed that
the lack of PSA response after initial hormonal manipulation might represent primary
resistance to hormonal therapy. This is particularly important, as other non‐hormonal
treatment such as chemotherapy should be considered early on, based on the prediction of
poor response to further hormonal manipulation.
5. Conclusions
PSA and PSA kinetics may provide additional information about the biological behaviour of
prostate cancer and may aid the treatment decision in an individualized approach. One should
be aware of the pros and cons of the different PSA‐related parameters and should be cautious
when interpreting the results from different studies. PSA and its kinetics should play an
important role in the management of advanced prostate cancer, and generalization can only
be achieved if definitions of the different parameters can be utilized in a more standardized
manner. Among the different parameters discussed, PSA progression appeared to be the most
consistent and reliable surrogate marker of survival and can serve as the primary endpoint in
future clinical trials.
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